Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial

Table 2 Baseline reticulocyte count, hematocrit, serum creatinine and eGFR with changes after cardiac surgery in patients randomized to placebo or rHuEPO group

	Placebo group (n = 50)	rHuEPO group (n = 50)	p value
Reticulocyte count, %
Baseline	1.19 ± 0.66	1.11 ± 0.63	0.53
Operative day (3 days after first dose)	1.12 ± 0.56	1.60 ± 0.82	<0.01
Hematocrit (%)
Baseline	36.7 ± 5.4	37.1 ± 5.2	0.72
Day 0 Pre-operation	36.8 ± 5.8	38.0 ± 5.2	0.31
Day 0 Post-operation	27.8 ± 4.0	29.4 ± 4.9	0.08
Day 1	32.3 ± 3.1	32.7 ± 3.1	0.45
Day 2	32.3 ± 3.4	32.9 ± 3.5	0.4
Day 3	32.3 ± 3.6	33.5 ± 3.9	0.17
Serum creatinine (SCr), mg/dL	1.05 ± 0.45	1.06 ± 0.25	0.83
Baseline
Day 1 after CABG	1.42 ± 0.53	1.28 ± 0.46	0.25
Day 2 after CABG	1.35 ± 0.44	1.06 ± 0.42	<0.05
Day 3 after CABG	1.18 ± 0.62	0.96 ± 0.38	0.15
eGFR, mL/min/1.73 m²
Baseline	67 ± 33	64 ± 29	0.44
Day 1 after CABG	56 ± 25	65 ± 27	<0.05
Day 2 after CABG	51 ± 28	62 ± 25	<0.05
Day 3 after CABG	58 ± 24	68 ± 26	<0.05

ISSN: 1471-2369